BioLife Solutions appoints Joydeep Goswami to board; Andrew Hinson retires after 14 years

BIOLIFE SOLUTIONS INC

Andrew Hinson retired from the BioLife board effective Oct 1, 2021; retirement not due to any disagreement with the company.
Joydeep Goswami, Ph.D., appointed to fill the vacancy; qualifies as independent under Nasdaq rules.
Goswami is chief strategy & corporate development officer at Illumina (ILMN) and previously president at Thermo Fisher (TMO).
Goswami will chair the Nominating and Governance Committee; compensation same as other non-employee directors.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Joydeep Goswami

Director

BLFS · BIOLIFE SOLUTIONS INC

Filed: October 7, 2021, 7:59 PM ET

the Board appointed Joydeep Goswami, Ph.D. to the Board

Departed

Andrew Hinson

Director

BLFS · BIOLIFE SOLUTIONS INC

Effective: 2021-10-01
Successor: Joydeep Goswami
Filed: October 7, 2021, 7:59 PM ET

Effective October 1, 2021, Andrew Hinson retired from the board of directors

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joydeep Goswami was appointed as Director at BIOLIFE SOLUTIONS INC.

Action: appointed
Role: Director

Exact text from the filing

the Board appointed Joydeep Goswami, Ph.D. to the Board

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Hinson retired as Director at BIOLIFE SOLUTIONS INC.

Action: retired
Role: Director

Exact text from the filing

Effective October 1, 2021, Andrew Hinson retired from the board of directors

View on SEC.gov

BIOLIFE SOLUTIONS INC filing history →

Source: SEC EDGAR

accession 0001437749-21-023402

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.